Mesa Laboratories, Inc. Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2013. The request metadata references “2011 Q4,” but the supplied filing is the fiscal 2013 annual report, including quarterly data for the quarter ended March 31, 2013.
Business Context
Mesa manufactures quality-control products for regulated niche markets through two divisions: Biological Indicators and Instruments. Biological Indicators products monitor sterilization processes and are relatively recurring and less economically sensitive. Instruments products include data loggers, medical meters, gas-flow calibration equipment, torque systems and fluid analyzers; instrument demand is more discretionary and economically sensitive.
The company operates facilities in Colorado, New Jersey, Montana and Nebraska and had 215 employees at March 31, 2013. In May 2012, Mesa acquired selected assets and liabilities of Bios International Corporation, expanding its Instruments business.
Key Financial Metrics
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Revenue | $46.435 million | $39.616 million | +17% |
| Gross profit | $28.862 million | $23.511 million | +23% |
| Gross margin | 62% | 59% | +3 percentage points |
| Operating income | $13.104 million | $12.477 million | +5% |
| Net income | $8.450 million | $7.919 million | +7% |
| Net profit margin | 18% | 20% | Down 2 percentage points |
| Diluted EPS | $2.35 | $2.29 | +3% |
| Operating cash flow | $11.402 million | $12.489 million | Down 9% |
Biological Indicators revenue increased 5% to $21.464 million, while Instruments revenue increased 30% to $24.971 million. Instruments benefited substantially from the Bios acquisition, while legacy Instruments revenue remained relatively unchanged. Biological Indicators gross margin improved to 58% from 55%; Instruments gross margin improved to 66% from 64%.
At March 31, 2013, cash and cash equivalents were $4.006 million, working capital was $14.793 million, total assets were $65.919 million and stockholders’ equity was $52.753 million. Accounts receivable increased to $8.474 million and inventory increased to $5.576 million.
Total debt was $4.000 million under a variable-rate revolving credit facility. The facility provides $20 million of revolving capacity and matures in February 2015. Mesa reported $16 million of unused capacity and compliance with its debt covenants at year-end. A 1 percentage-point increase in interest rates would have increased annual interest expense by approximately $70,000.
Material Changes Versus Prior Period
- Revenue increased $6.819 million, primarily from the Bios acquisition, organic Biological Indicators growth, market expansion and price increases.
- Gross profit increased $5.351 million, aided by acquisition integration and manufacturing efficiencies.
- General and administrative expense increased 68% to $9.117 million. Drivers included Bios-related amortization and personnel costs, CFO transition costs, ERP and Sarbanes-Oxley compliance work, stock-based compensation and acquisition-related expenses.
- Research and development expense increased 48% to $2.011 million.
- Cash declined $3.185 million during the year, principally because the $16.660 million Bios acquisition and $0.908 million of capital expenditures exceeded operating cash flow and financing inflows.
- Debt increased from zero at March 31, 2012 to $4.000 million at March 31, 2013 after $11.000 million of acquisition borrowing and $7.000 million of principal repayments.
- Goodwill increased by $9.190 million and net intangible assets increased to $15.418 million as a result of the Bios acquisition. No impairment charge was recorded in FY2013; FY2012 included a $350,000 intangible-asset impairment charge.
- Quarterly dividends increased from $0.12-$0.13 per share in FY2012 to $0.13-$0.14 per share in FY2013. A $0.14 per-share dividend was declared in April 2013.
Outlook, Risks and Unusual Items
Management expects continued growth from organic initiatives and potential acquisitions. It described the Biological Indicators market as strong and less sensitive to economic conditions, while noting that general economic weakness has slowed organic Instruments growth. Management was pursuing research and development projects that could produce new products in the following year.
- The Bios acquisition includes contingent consideration based on cumulative acquired-business revenue exceeding $22.127 million over three years. The potential undiscounted payment ranges from zero to $6.710 million; the recorded liability was $2.140 million and is payable in the first quarter of fiscal 2016. Changes from the recorded estimate would affect income or expense.
- Mesa became subject to a 2.3% medical-device excise tax on applicable domestic sales beginning January 1, 2013. Recovery of the full cost through pricing is not assured.
- The company identified potential state sales-tax obligations. It recorded $100,000 for one state, but stated that additional exposure was not estimable and could adversely affect results.
- FY2013 included approximately $240,000 of incremental stock-compensation expense from modifying former CFO Steven Peterson’s options and a separation payment included in other compensation.
- Risks include competition from larger companies, economic weakness affecting Instruments demand, acquisition integration and impairment risk, regulatory and FDA compliance, product liability, dependence on distributors and certain suppliers, variable-rate debt, intellectual-property protection and sales-tax exposure.
- Approximately 40% of sales were to foreign customers, creating international operating and collection considerations, although foreign-currency and commodity-market exposure was described as minimal.
Facts Investors Should Verify
- Reconcile the requested “2011 Q4” period with the supplied FY2013 Form 10-K and confirm whether fiscal 2013 annual or March 31, 2013 quarterly results are intended.
- Assess the sustainability of revenue and margin gains attributable to the Bios acquisition versus organic growth, particularly given that legacy Instruments revenue was relatively flat.
- Review the $2.140 million Bios contingent-consideration liability and the potential payment range through fiscal 2016.
- Quantify unresolved state sales-tax exposure and monitor the effect of the medical-device excise tax on pricing and margins.
- Evaluate liquidity after the acquisition, including $4.000 million of debt, the February 2015 facility maturity, covenant requirements and the April 2013 $1.000 million principal payment.
- Monitor working-capital trends, especially the increase in receivables and inventory and the decline in operating cash flow.
- Review goodwill and intangible-asset balances and future amortization, including estimated FY2014 amortization of $2.355 million.